Published in Stem Cell Week, January 25th, 2010
"Hence, we hypothesized that measles virotherapy of ovarian cancer in measles-immune mice might be superior if MV-infected mesenchymal stem cell (MSC) carriers are used. Antimeasles antibodies titers in ovarian cancer patients were determined. The protection of MV by MSC from antimeasles antibodies, the in vivo bio-distribution profiles, and tumor infiltration capability of MSC were...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Stem Cell Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.